company background image
4119 logo

SCI Pharmtech TWSE:4119 Stock Report

Last Price

NT$87.90

Market Cap

NT$10.5b

7D

-0.6%

1Y

-19.9%

Updated

24 Apr, 2024

Data

Company Financials

4119 Stock Overview

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals.

4119 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends1/6

SCI Pharmtech, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SCI Pharmtech
Historical stock prices
Current Share PriceNT$87.90
52 Week HighNT$116.44
52 Week LowNT$85.60
Beta-0.16
1 Month Change0.34%
3 Month Change-6.98%
1 Year Change-19.93%
3 Year Change30.12%
5 Year Change25.97%
Change since IPO343.19%

Recent News & Updates

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Mar 27
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Recent updates

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Mar 27
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Apr 07
Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Mar 30
There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

Mar 08
SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Jan 25
SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Dec 30
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Dec 29
Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

Dec 08
Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Nov 17
A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Shareholder Returns

4119TW PharmaceuticalsTW Market
7D-0.6%-2.2%-1.6%
1Y-19.9%7.2%25.9%

Return vs Industry: 4119 underperformed the TW Pharmaceuticals industry which returned 7.2% over the past year.

Return vs Market: 4119 underperformed the TW Market which returned 25.9% over the past year.

Price Volatility

Is 4119's price volatile compared to industry and market?
4119 volatility
4119 Average Weekly Movement1.9%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.6%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 4119 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4119's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aWen-Chih Chouwww.sci-pharmtech.com.tw

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company’s intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol.

SCI Pharmtech, Inc. Fundamentals Summary

How do SCI Pharmtech's earnings and revenue compare to its market cap?
4119 fundamental statistics
Market capNT$10.49b
Earnings (TTM)NT$294.72m
Revenue (TTM)NT$1.20b

35.6x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4119 income statement (TTM)
RevenueNT$1.20b
Cost of RevenueNT$853.84m
Gross ProfitNT$350.32m
Other ExpensesNT$55.60m
EarningsNT$294.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.47
Gross Margin29.09%
Net Profit Margin24.48%
Debt/Equity Ratio20.3%

How did 4119 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

46%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.